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Abstract  68 
Perturbations in the intrauterine environment can result in lifelong consequences for metabolic 69 
health during postnatal life. Intrahepatic cholestasis of pregnancy (ICP) can predispose 70 
offspring to metabolic disease in adulthood, likely due to a combination of the effects of 71 
increased bile acids, maternal dyslipidemia and deranged maternal and fetal lipid homeostasis. 72 
Whereas ursodeoxycholic acid (UDCA) is a commonly used treatment for ICP, no studies have 73 
yet addressed whether it can also prevent the metabolic effects of ICP in the offspring and 74 
fetoplacental unit. We therefore analyzed the lipid profile of fetal serum from untreated ICP, 75 
UDCA-treated ICP and uncomplicated pregnancies and found that UDCA ameliorates ICP-76 
associated fetal dyslipidemia. We then investigated the effects of UDCA in a mouse model of 77 
hypercholanemic pregnancy and showed that it induces hepatoprotective mechanisms in the 78 
fetal liver, reduces hepatic fatty acid synthase (Fas) expression and improves glucose tolerance 79 
in the adult offspring. Finally, we showed that ICP leads to epigenetic changes in pathways of 80 
relevance to the offspring phenotype. We therefore conclude that UDCA can be used as an 81 
intervention in pregnancy to reduce features of metabolic disease in the offspring of 82 
hypercholanemic mothers.   83 
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Introduction 102 
The prevalence of non-communicable diseases such as obesity and type 2 diabetes has grown 103 
rapidly over the last three decades (1). Increasing evidence links gestational, perinatal and early 104 
infancy factors to susceptibility of metabolic disease in adulthood (2). Type 2 diabetes is more 105 
prevalent among people whose mothers experienced malnutrition during the Dutch famine in 106 
1944-45 (3), and a substantive literature suggests that maternal obesity and gestational diabetes 107 
mellitus (GDM) are associated with elevated metabolic syndrome markers in childhood and 108 
later life (4). These observational studies have been strengthened by studies in animal models, 109 
which have shown that the maternal nutritional and metabolic status can profoundly influence 110 
cardiovascular and metabolic function in young and adult offspring (5–7).  111 
Intrahepatic cholestasis of pregnancy (ICP) affects 0.5% of pregnancies in UK and up to 2% 112 
globally (8). Its etiology is complex, with genetic and endocrine components. A subgroup of 113 
affected women possess genetic variants in biliary transporters (ABCB4/MDR3 and 114 
ABCB11/BSEP) and nuclear receptors (NR1H4/FXR) that perturb bile acid (BA) homeostasis 115 
(9, 10). The phenotype of ICP is unmasked by pathologically elevated levels of reproductive 116 
hormone metabolites in genetically predisposed women (11–14). Women with ICP present 117 
with pruritus, hepatobiliary injury and hypercholanemia (elevated serum BA concentrations), 118 
as well as dyslipidemia (2, 3, 15). Increased rates of GDM have been reported (15, 16). 119 
Maternal BA concentrations ≥40μmol/L are associated with adverse fetal outcomes, including 120 
spontaneous preterm labor, fetal hypoxia and meconium-stained amniotic fluid (17–19). Fetal 121 
BA levels are raised in umbilical cord blood in ICP pregnancies (20). 122 
Exposure of the fetus to elevated BA in utero as a result of ICP predisposes the adolescent 123 
offspring to metabolic disease. Analysis of the Northern Finland Birth cohort database (1986) 124 
revealed that 16-year old children from cholestatic pregnancies had increased body mass index 125 
and dyslipidemia, and the males had raised fasting insulin compared to age matched 126 
adolescents of uncomplicated pregnancies (21). In a mouse model of 0.5% cholic acid (CA) 127 
feeding that replicates the hypercholanemia of cholestatic pregnancy, female offspring exposed 128 
to increased BAs in utero developed hepatic steatosis, glucose intolerance and insulin 129 
resistance when challenged with a Western diet (WD) for six weeks. Human samples and in 130 
vivo experiments showed that increased transplacental cholesterol transport and greater fat 131 
storage in the fetoplacental unit contribute to this phenotype (21). Furthermore, maternal 132 
hypercholanemia resulted in altered DNA methylation patterns in the agouti Avy yellow mouse 133 
offspring, implicating epigenetic alterations in the ICP-associated offspring phenotype (21).  134 
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Administration of ursodeoxycholic acid (UDCA) is a treatment for ICP that reduces BA levels 135 
and improves symptoms and biochemical abnormalities in the mother. However, it is not 136 
known whether UDCA improves fetal abnormalities and susceptibility of the offspring to 137 
metabolic disease later in life (22, 23). 138 
We hypothesized that treatment with UDCA in cholestatic pregnancy can reverse the fetal 139 
metabolic phenotype, as well as placental dyslipidemia. This may also prevent features of 140 
metabolic syndrome in the adult offspring. To address our hypothesis, we first compared the 141 
fetal and maternal biochemical profile in UDCA-treated ICP pregnancies, untreated ICP and 142 
uncomplicated pregnancies. Based on these findings, we then administered UDCA in a mouse 143 
model of maternal hypercholanemia to mimic UDCA treatment in ICP (21) and we investigated 144 
the impact on the metabolic phenotype of the adult offspring. Based on our previous findings 145 
in the agouti Avy yellow mouse models and the emerging evidence that epigenetic processes in 146 
early life stages are key factors that influence metabolism (24, 25), we also explored 147 
modifications in the methylation patterns of umbilical cord leukocytes and placentas from 148 
human ICP using an epigenome-wide association study (EWAS) and global methylation 149 
studies.   150 
 151 
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Methods 153 
Human samples. Women with untreated ICP (n=16), UDCA-treated ICP (n=17) and controls 154 
(n=18) were recruited from Queen Charlotte’s and Chelsea and St Thomas’ Hospitals, London. 155 
ICP diagnosis was based on presentation with gestational pruritus and serum BA over 10 156 
µmol/L and no additional identifiable cause of liver dysfunction. Exclusion criteria included 157 
other causes of hepatic dysfunction (including pre-eclampsia, hemolysis, elevated liver 158 
enzymes, and low platelets (HELLP) syndrome, acute fatty liver of pregnancy, primary biliary 159 
cholangitis, active viral hepatitis, and any ultrasound abnormality that may result in biliary 160 
obstruction) and multi-fetal pregnancy. Controls were women with uncomplicated pregnancy. 161 
The decision to treat with UDCA was made by the individual specialist clinician looking after 162 
each woman with ICP. Maternal serum and umbilical cord blood were collected and prepared 163 
as previously described (20). 164 
 165 
Animal handling and maintenance. Age-matched (6-8-week-old) female and male C57BL/6 166 
inbred mice were purchased from Harlan Laboratories (Derbyshire, UK) and maintained in a 167 
24-hour light-dark cycle (12h/12h) with free access to normal chow diet (RM3; SDS, Essex, 168 
UK) and water. Mice were allowed to acclimatize for one week before any experiment. For all 169 
studies, the second litters were used as previously described (21). A week before mating for 170 
the second litter, females were randomly assigned to one of the three dietary groups: RM3 171 
control diet (normal chow-NC; n=6), RM3 diet supplemented with 0.5% CA (CA diet; n=6) or 172 
RM3 diet supplemented with 0.5% CA plus 0.5% UDCA (CA+UDCA diet; n=4). All diets 173 
were purchased from LBS Serving Biotechnology Ltd, Horley, UK. To address the effects of 174 
UDCA in gestational cholestasis, pregnant mothers were sacrificed on day 18 of pregnancy 175 
after a 4-hour fast. Maternal and fetal liver and blood as well as placentas were collected. 176 
Maternal body weight, liver weight, litter number, fetal weight and placental weight were 177 
monitored.  178 
To investigate the effects of UDCA on long-term health of the offspring, a different set of mice 179 
were placed on an identical maternal dietary regime and were allowed to give birth to offspring 180 
(n=4-6 mothers per dietary regimen). Litters were reduced to four mice per mother on post-181 
natal day 2; 2 females and 2 males from each mother were kept when possible. Only female 182 
offspring were analyzed in this study, as it was previously shown that females from this dietary 183 
regime develop a more extreme phenotype (21). At 12 weeks of age, one female mouse from 184 
each litter was challenged with a western diet for six weeks (LBS Serving Biotechnology Ltd), 185 
whereas female littermates continued on a NC diet (n=4-6 per dietary regimen from each 186 
 7 
different diet mothers). A glucose tolerance test was performed two days before sacrifice of 187 
the animals at 18 weeks of life as previously described (intraperitoneal injection, 2g/kg) (21). 188 
 189 
Biochemical measurements. Serum and tissue biochemical parameters (total, LDL- and HDL-190 
cholesterol, triglycerides (TG) and FFA) were measured using an LX20 autoanalyzer 191 
(Beckman Coulter) as previously described (21). BA measurements were performed by ultra-192 
performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) with the use 193 
of internal standards for extraction and quantification as previously reported (11). The same 194 
techniques were used for both human and animal studies.  195 
 196 
Epigenome wide association studies (EWAS): Venous umbilical cord samples were collected 197 
from pregnancies affected by ICP (n=43; 22 of which received treatment with UDCA) and 198 
uncomplicated pregnancies (n=17). Samples were collected in plain vacutainers and 199 
centrifuged at 3500 rpm for 10 minutes. The serum was stored at -80ᵒC until use. EDTA blood 200 
collection tubes were used to store whole blood at -80oC. DNA was extracted using the Qiagen 201 
Qiamp Blood mini kit, according to the manufacturers instructions (Qiagen, Skelton House, 202 
Manchester, UK). Following elution of DNA into AE buffer, samples were returned to storage 203 
at -80oC until use. 1µg of the genomic DNA was treated with Sodium Bisulfite using Zymo 204 
EZ DNA Methylation-Gold kit (ZymoResearch, Irvine, California, USA, D5007) and 205 
processing of the  HumanMethylationEPIC (Illumina, Inc. CA, USA) platform was carried out 206 
by the Centre for Molecular Medicine and Therapeutics (CMMT) (http://www.cmmt.ubc.ca).  207 
Raw image array files were processed using the R statistical software (R version 3.5.0). A total 208 
of 866,836 probes for 60 samples were analysed with minfi (version 1.26) and probe signals 209 
normalised using the stratified quantile normalisation algorithm (26). We identified probes that 210 
were detected (P > 0.01) in one or more samples (n=863,110) and were not at the sites of single-211 
nucleotide polymorphisms (SNPs) (minor allele frequency – maf = 0) (26)(n=833,907) or 212 
cross-reactive (identified for the EPIC dataset (27)). After excluding probes that did not meet 213 
all these criteria, a total of 792,068 probes, including those on sex chromosomes, were 214 
maintained for subsequent analyses. 215 
Statistical analyses for the methylation data were performed using the logit transformed M-216 
values for methylation to avoid bias that would have incurred if beta values were selected (28). 217 
Differentially methylated CpGs (dmCpGs) were assigned using Limma (version 3.36.1)  (29) 218 
adjusted for status, gender and ethnicity as confounders as well as treatment, gender and 219 
ethnicity in the second model. A 5% Benjamini-Hochberg False Discovery Rate (FDR) (30) 220 
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correction for multiple testing was applied. All dmCpGs were assigned to their corresponding 221 
genomic context and location using the R/Bioconductor package 222 
IlluminaHumaMethylationEPICanno.ilm10b2.hg19 (version 0.6.0) (31).  223 
Top 1000 dmCpGs, with a p value < 1.74E-04 and FDR <13%, were selected from the disease 224 
(treated and untreated) vs control probe-wise differential methylation analyses to perform IPA 225 
pathway analyses (QIAGEN Inc., version 01-07). The increase in FDR was adjusted to 226 
maintain a significant number of CpGs (32), including 18 passing FDR at 5%.  227 
 228 
Differentially methylated regions were identified using the DMRcate package (version 1.16.0) 229 
(33). Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses 230 
were performed with R/Bioconductor package missMethyl (version 1.14.0) using the gometh 231 
function (34) and the MethylationEPIC genes as background. Further pathway analyses were 232 
completed with Ingenuity IPA (QIAGEN Inc., version 01-07) utilising the Ingenuity 233 
knowledge base reference gene set. An IPA search of individual genes was also run to establish 234 
their biological significance.  235 
 236 
Global DNA methylation studies. DNA extraction of placentas was carried out with a DNeasy 237 
Blood and Tissue Kit (Qiagen) per supplier’s instructions. DNA was eluted in buffer AE, which 238 
guarantees optimal DNA stability, and stored at -20°C for further use. Quantification of DNA 239 
methylation was performed using the Epigentek MethylFlash Methylated DNA Kit 240 
(colorimetric assay; Insight Biotechnology Ltd, Wembley, UK), according to manufacturer’s 241 
instructions. 200ng of sample DNA as well as positive and negative controls were included. 242 
The light absorbance was quantified in a microplate reader at 450nm (Pherastar FS, BMG 243 
Labtech, Bucks, UK). Final amounts were calculated as percentages based on the controls’ 244 
standard curve as instructed by the manufacturer.  245 
 246 
Quantitative real-time PCR. 1μg of total RNA (Qiagen, Manchester UK) from mouse tissues 247 
and human placentas was processed as previously described (21). Primer sequences (Sigma-248 
Aldrich, Poole, UK) are given in Supplementary Table 1. 249 
 250 
Statistical analysis. Data are presented as means ± sem unless otherwise stated. Statistical 251 
analysis for multiple comparisons was performed by repeated measures of ANOVA and 252 
Newman–Keuls post hoc testing with the GraphPad Prism 7.00 software (GraphPad Software 253 
Inc., San Diego, CA, USA). The significance cutoff was set at p≤ 0.05. 254 
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 255 
Study approval. Written informed consent was received from participants prior to inclusion in 256 
the study, which conformed to the 1975 Declaration of Helsinki guidelines. Biochemical 257 
studies were approved by the local ethics committee of Hammersmith Hospital NHS Trust 258 
(11/L0/0396). Epigenome-wide studies were also permitted from the ethics committees of 259 
Hammersmith Hospitals NHS Trust, London (97/5197 and 08/H0707/21), and King’s College 260 
Hospitals NHS Trust, London (03WH06).  261 
All experimental procedures were approved by the ethical committee for animal welfare at 262 
King’s College London, and all animal studies were compliant with the UK Animals (Scientific 263 
Procedures) Act of 1986 and the guidelines from the biological sciences unit at King’s College 264 
London. 265 
 266 
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Results 268 
UDCA improves fetal dyslipidemic features associated with ICP  269 
ICP is associated with umbilical cord blood dyslipidemia and metabolic syndrome in 16-year-270 
old children (21). Analysis of umbilical cord blood lipid profiles in fetal cord blood from ICP 271 
+ UDCA treatment showed an increase in cholesterol and FFA in females exposed to ICP, 272 
whereas FFA and TG were increased in exposed males. These features were reversed by UDCA 273 
treatment (Figure 1). 274 
 275 
UDCA improves elevated maternal BA concentrations associated with CA feeding and 276 
induces fetal hepatoprotective mechanisms in mouse hypercholanemic pregnancy 277 
Due to the positive effects of UDCA on ICP-induced fetal dyslipidemia and the limited options 278 
for in vivo human fetal studies in ICP, we expanded our studies into a mouse model in which 279 
a 0.5% (CA) diet fed to pregnant mice mimicked the hypercholanemia of ICP, as previously 280 
described (21). We first investigated whether dietary supplementation with UDCA is sufficient 281 
to reverse the CA diet-induced increase in maternal and fetal BA concentrations (CA+UDCA). 282 
UDCA prevented the elevation of taurocholic acid (TCA) and taurodeoxycholic acid (TDCA) 283 
in maternal serum and liver (Figure 2A). However, UDCA did not affect the altered mRNA 284 
expression of CA diet-induced Fxr targets such as Shp, Cyp7a1 and Bsep (Figure 2B). Unlike 285 
maternal BA levels, UDCA did not significantly reversed the CA diet-induced increase in fetal 286 
serum BAs (Figure 2C). UDCA did not alter fetal hepatic Cyp7a1 and Shp mRNA expression 287 
(Figure 2D).  288 
As UDCA did not block CA diet-induced serum BAs and hepatic Fxr targets in the fetus, we 289 
investigated whether UDCA can induce fetal hepatoprotective mechanisms. To address this, 290 
we studied the gene expression profile of BA transporters in the fetal liver affected by 291 
hypercholanemia. UDCA increased Mrp2 and Oatp1a1 mRNA, whereas it reversed the Bsep 292 
mRNA upregulation caused by gestational hypercholanemia in the fetal liver (Figure 3). No 293 
statistically significant changes were observed in gene expression of fetal hepatic Oatp1b2 and 294 
Mrp3 mRNA.  295 
We previously showed that maternal hypercholanemia in the mouse increased liver to body 296 
weight ratio, as well as placental weight. UDCA reversed the increase in placental weight, but 297 
it did not affect the maternal liver to body weight ratio (Supplementary Figure 1). 298 
 299 
 300 
 301 
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UDCA improves hypercholanemia-induced maternal and fetal dyslipidemia in the mouse  302 
We previously established that, in line with ICP, mouse hypercholanemic pregnancy results in 303 
maternal and fetoplacental dyslipidemia (15, 21). As shown in Figure 4A, UDCA prevented 304 
the CA diet-induced changes in total, HDL- and LDL-cholesterol in maternal serum. It also 305 
reduced hepatic TG and cholesterol levels. In the fetal serum, UDCA reversed the decrease in 306 
HDL cholesterol and the increase in TG levels, (Figure 4B). Also, UDCA supplementation in 307 
hypercholanemic pregnancy reversed the increase of cholesterol and TG levels in the placenta 308 
(Figure 4C). However, UDCA did not affect the dyslipidemic phenotype of the fetal liver 309 
(Figure 4B). 310 
To further investigate whether maternal and fetal serum lipid profiles are associated with 311 
changes in hepatic metabolism, we looked at the transcription of hepatic rate-limiting 312 
cholesterol and fatty acid synthesis genes, HMG-CoA reductase (Hmgcr) and fatty acid 313 
synthase (Fas) mRNA. No effects were observed in the hepatic Hmgcr mRNA either in the 314 
mother or fetus in response to UDCA (Figures 5A and 5C). In contrast, UDCA prevented the 315 
CA-associated increase of Fas mRNA in the fetal liver (Figure 5D) but not in the maternal liver 316 
(Figure 5B).  317 
 318 
UDCA in mouse hypercholanemic pregnancy improves glucose tolerance in female 319 
offspring 320 
We previously established that female adult offspring exposed to CA in utero develop glucose 321 
intolerance when fed a WD for six weeks (21). We therefore tested whether exposure of the 322 
offspring to UDCA in pregnancy can ameliorate this phenotype. Although UDCA did not affect 323 
the liver to body weight ratio (Figure 6A), it did significantly improve glucose tolerance in 18-324 
week old female offspring (Figure 6B). Remarkably, whereas offspring fed a NC diet 325 
responded to intraperitoneal glucose injection within 15’ regardless of the maternal dietary 326 
regime during pregnancy (Figure 6B, left panel), offspring fed a WD diet who were exposed 327 
to UDCA in utero did not develop glucose intolerance (Figure 6B, right panel). Intriguingly, 328 
30’ after the intraperitoneal glucose injection, blood glucose levels were significantly 329 
decreased in WD-fed females exposed to UDCA in gestation compared to WD-fed females 330 
from NC- or CA-fed mothers (Figure 6B). 331 
 332 
 333 
 334 
 335 
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ICP alters DNA methylation profiles of relevance to offspring phenotype 336 
Eighteen CpGs were differentially methylated (with a 5% Benjamini-Hochberg FDR) when all 337 
cases of ICP (treated and untreated, labelled as disease group) were compared to controls 338 
(control versus disease comparison, Table 1). Specifically, these dmCpGs were located mainly 339 
in the gene body (TEX29, TBX1, MAMDC2, WDFY4, AHNAK, NFIA and WDR70); within 340 
the 5' untranslated region, between the TSS and the ATG start site (H6PD, ILR21, DFNB59) 341 
and one was located in the 3’UTR, between the stop codon and poly A signal (PYCR2) (Table 342 
1). An IPA search of the genes associated with the DMCpGs was then performed to analyse 343 
their biological significance. H6PD is related to carbohydrate metabolism biological processes, 344 
whilst AHNAK is related to impaired glucose tolerance. When analyses were run to include 345 
the treatment as a factor in the model, both the control versus untreated and also the treated 346 
versus untreated comparisons identified two significantly differentially methylated CpGs, all 347 
assigned to the PRR25 gene (located within the CpG island, Table 1), which does not have any 348 
known direct relevance to the phenotype.    349 
To further analyse the biological importance of the methylation differences in each 350 
comparison, canonical pathways were identified using IPA, GO and KEGG tools through the 351 
MissMethyl R package. In the control versus disease analysis, IPA identified 45 pathways that 352 
were differentially methylated, including one related to fatty acid oxidation (Figure 7). 353 
Additional pathways were identified with the R gometh function in the MissMethyl package 354 
by GO and KEGG (Table 2). IPA analysis, using the Ingenuity knowledge base reference gene 355 
set, also highlighted the presence of gene promoters that were differentially methylated 356 
between controls and disease (Figure 8B). Similarly, several disease processes were revealed 357 
for the same comparison, including endocrine system disorders, lipid metabolism, 358 
carbohydrate metabolism and metabolic disease (Figure 8A).    359 
 360 
ICP affects the methylation profile of human placentas  361 
The placenta plays an important role in transferring maternal environmental cues to the fetus, 362 
thereby potentially influencing metabolic programming (35). Placentas from ICP pregnancies 363 
had a significant increase in global methylation when compared to placentas from 364 
uncomplicated pregnancies (Figure 9).  365 
  366 
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Discussion     367 
In this study we demonstrated for the first time that UDCA has a protective role against the 368 
development of ICP-associated fetal dyslipidemia. If persistent, these effects may protect 369 
offspring from the development of metabolic disease in later life. Using a model of mouse 370 
gestational hypercholanemia that was also administered UDCA, we showed a similar effect in 371 
the mother and fetus. In addition, UDCA prevented the development of glucose intolerance in 372 
the obese offspring of these mice. We also showed for the first time that ICP induces 373 
epigenomic alterations in fetal cord blood. Similarly, maternal hypercholanemia altered global 374 
methylation patterns in human placentas.   375 
 A limited number of studies have assessed effects of UDCA on the fetoplacental unit and 376 
whether it may have a beneficial role for the long-term health of the offspring. One previous 377 
study revealed raised numbers of syncytial knots in ICP placentas, indicating that elevated BA 378 
concentrations in ICP are associated with increased apoptosis (36). These observations were 379 
consistent with a study in a rat model of gestational hypercholanemia that demonstrated 380 
increased apoptosis and oxidative stress in placentas exposed to excessive BA (37). Another 381 
study reported a UDCA-induced reversal of transient latent cholestasis in 21-day old offspring 382 
from a rat model of hypercholanemic pregnancy (38). In ICP, UDCA has also been shown to 383 
reduce BA levels in umbilical cord blood and amniotic fluid (39, 40).  384 
While in our mouse model UDCA successfully reversed maternal gestational 385 
hypercholanemia, it did not reverse increased BA concentrations in the fetal serum. However, 386 
we showed UDCA-associated induction of fetal hepatic BA transporters, and this may reduce 387 
fetal BA toxicity. It is likely that the upregulation of Mrp2 and Oatp1a1 in the fetal liver 388 
protects the fetus from hepatocellular accumulation of potentially toxic biliary constituents. In 389 
support of this, an increase of Mrp2 mRNA has been reported in rat cholestasis (41).  390 
Interestingly, we not only showed that UDCA improved fetal and maternal dyslipidemia in our 391 
animal model, but also that it had an impact on FFA synthesis pathways in the fetus. Unlike in 392 
the maternal liver, fetal hepatic Fas mRNA expression returned to baseline when 393 
hypercholanemic mothers were administered UDCA.  This finding is of interest as FFA 394 
accumulation in the hepatocyte has been implicated in the development of hepatosteatosis (33), 395 
which is one of the long-term effects of maternal hypercholanemia in the offspring of this 396 
model (21). Emerging evidence suggests that hepatosteatosis precedes the metabolic syndrome 397 
and is associated with insulin resistance (42). We previously established in this model that mild 398 
hepatosteatosis precedes progression of glucose intolerance that is unmasked when the 399 
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offspring are fed an obesogenic diet. Herein, we report that WD-fed female offspring exposed 400 
to UDCA in utero were protected from impaired glucose tolerance.  401 
This concurs with previous studies in rodents that have successfully improved obesity-induced 402 
hepatosteatosis with UDCA administration (43, 44). A permanent effect of UDCA on the 403 
pathogenesis of non-alcoholic fatty liver disease (NAFLD) and associated impairment of 404 
metabolic health is therefore plausible, and might be attributable to the restoration of a healthy 405 
FFA metabolism. 406 
UDCA reduced hepatic TG in hypercholanemic mothers, as well as in the fetal serum and 407 
placenta. It also reversed the hypercholesterolemic phenotype of the mother and placentas, and 408 
the CA-induced reduction in HDL levels in the fetal serum. Curiously, these results were not 409 
accompanied by a reduction in mRNA expression of maternal and fetal hepatic cholesterol de 410 
novo biosynthesis gene Hmgcr, suggesting that UDCA mediates these effects via alternative 411 
mechanisms.   412 
DNA methylation is a typical chromatin modification that can occur when the mother is 413 
exposed to an environmental stimulus. We previously established that female offspring of the 414 
Avy mouse model, when born to mothers fed a CA diet, have reduced methylation of the IAP 415 
promoter (21), suggesting that maternal hypercholanemia can trigger epigenetic changes in the 416 
offspring. By performing an EWAS in fetal umbilical cord blood, we found that ICP also 417 
induces methylation changes in pathways that could contribute to the offspring phenotype. 418 
When ICP cases (both treated and untreated) were compared with controls (uncomplicated 419 
pregnancies), a total of eighteen differentially methylated CpGs were found. IPA pathway 420 
analysis showed that these methylated CpGs are involved in fatty acid oxidation pathways, as 421 
well as pathways potentially related to glucose metabolism such as glucose-6-phosphate 422 
dehydrogenase activity and glucose 1-dehydrogenase [NAD(P)] activity. Interestingly, such 423 
pathways are involved in diseases related to endocrine system, cardiovascular disease, lipid 424 
metabolism, carbohydrate metabolism, and metabolic disease, all of which are consistent with 425 
our previous findings.  426 
The control versus untreated and the treated versus untreated comparisons yielded limited 427 
results and did not identify any loci directly relevant to the phenotype studied. The relatively 428 
small number of samples precluded detailed investigation of whether beneficial effects of 429 
UDCA stem from epigenetic changes or not. Another limitation of the analysis is that the 430 
samples from UDCA-treated and untreated ICP cases were not matched for disease severity as 431 
they would be in a randomised, placebo-controlled trial.  432 
While the use of surrogate tissues for human EWAS offers valuable insights into the 433 
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epigenome, it also presents a challenge for interpretation due to possible tissue-specific 434 
epigenetic alterations. However, alterations in DNA methylation in the placenta have been 435 
previously reported (36), suggesting that placental epigenetic marks may be of relevance to 436 
metabolic homeostasis in later life.  437 
To gain further insight into the epigenetic component of hypercholenemic pregnancy, we also 438 
performed a global DNA methylation analysis of human placentas. As suggested by the EWAS 439 
results, ICP altered the human placental epigenome.  440 
 441 
Conclusion 442 
UDCA treatment improves ICP-associated fetal dyslipidaemia. This finding is consistent in 443 
mouse hypercholanemic pregnancy. In addition, maternal UDCA administration improved the 444 
lipid profile of mothers and placentas and triggered hepatoprotective mechanisms in the fetal 445 
liver in mouse gestational hypercholanemia. In adult offspring, UDCA prevented the 446 
development of glucose intolerance. Our data support an epigenetic component to the impact 447 
of ICP upon offspring metabolic phenotypes. Larger sample sizes will enable more detailed 448 
assessment of the effects of UDCA on the epigenome, and investigation of sex-specific 449 
alterations. Human cohort studies will be necessary to investigate whether such UDCA effects 450 
can persist through adulthood. These data indicate that UDCA may be used as an effective 451 
intervention in ICP to prevent susceptibility of the adult offspring  to metabolic disease. 452 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
 466 
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Figure legends 619 
 620 
Figure 1: Serum biochemical profile of umbilical cord blood from uncomplicated 621 
pregnancies, untreated ICP and UDCA-treated ICP. n= 18, 16 and 17, respectively. Data 622 
are presented as mean and standard error of the mean (SEM) and were analyzed with multiple 623 
measures of ANOVA followed by Neuman Keul’s post-hoc testing. a: p<0.05 for comparison 624 
ICP vs Control in females; b: p<0.05 for comparison ICP vs ICP + UDCA; c: p<0.05 for 625 
comparison ICP vs Control in males; d: p<0.05 for comparison ICP vs ICP + UDCA males; 626 
ICP: intrahepatic cholestasis of pregnancy; UDCA: ursodeoxycholic acid; FFA: free fatty 627 
acids; TG: triglycerides.  628 
 629 
Figure 2: Effects of UDCA on mouse bile acid homeostasis.  A) UDCA supplementation in 630 
0.5% CA-fed mice reversed increased taurine-conjugated bile acids in the maternal serum and 631 
liver. B) UDCA did not affect  maternal mRNA expression levels of Fxr target genes. C) 632 
UDCA supplementation in CA feeding did not affect taurine-conjugated bile acids in the fetal 633 
serum D) UDCA supplementation in CA feeding did not affect Shp or Cyp7a1 mRNA 634 
expression levels. Data are presented as mean and standard error of the mean (SEM) and were 635 
analyzed with multiple measures of ANOVA followed by Neuman Keul’s post-hoc testing. 636 
*p<0.05 between comparisons connected by lines; NC n=6, C A n=6, CA+UDCA n=4. NC, 637 
CA and CA+UDCA represent maternal diet. 638 
 639 
Figure 3: Effects of UDCA on fetal hepatic bile acid transporters.  Gene expression profile 640 
of the BA transport genes Mrp2, Mrp3, Bsep, Oatp1a1 and Oatp1b2 mRNA in mouse fetal 641 
liver. Data are presented as mean and standard error of the mean (sem) and were analyzed with 642 
multiple measures of ANOVA followed by Neuman Keul’s post-hoc testing. *p<0.05 between 643 
comparisons connected by lines, NC n=6, CA n=6, CA+UDCA n=4. NC, CA and CA+UDCA 644 
represent maternal diet.  645 
 646 
Figure 4: Effects of UDCA on lipid profile in mouse hypercholanemic pregnancy.  A) 647 
UDCA improved maternal serum cholesterol and LDL-cholesterol as well as hepatic 648 
cholesterol increase in gestational cholestasis. B) UDCA reversed cholestasis induced changes 649 
in HDL and TG in the fetal serum, but it did not affect cholesterol and TG raised levels in the 650 
fetal liver. C) UDCA reversed cholesterol and TG elevated levels associated with maternal 651 
cholestasis in placenta. Data are presented as mean and standard error of the mean (sem) and 652 
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were analyzed with multiple measures of ANOVA followed by Neuman Keul’s post-hoc 653 
testing. *p<0.05 between comparisons connected by lines. NC n=6, CA n=6, CA+UDCA n=4. 654 
NC, CA and CA+UDCA represent maternal diet. FFA: free fatty acids; HDL: high-density 655 
lipoprotein; LDL: low-density lipoprotein; TG: triglyceride.  656 
 657 
Figure 5: Effects of UDCA on lipid gene expression profile in mouse hypercholanemic 658 
pregnancy.  A) Hmgcr mRNA expression in maternal liver. B) Fas mRNA expression in 659 
maternal liver C) Hmgcr mRNA expression in fetal liver D) Fas mRNA expression in fetal 660 
liver. Data are presented as mean and standard error of the mean (sem) and were analyzed with 661 
multiple measures of ANOVA followed by Neuman Keul’s post-hoc testing. NC n=6, CA n=6, 662 
CA+UDCA n=4.  *: p<0.05 between comparisons connected by lines. NC: normal chow; CA: 663 
diet supplemented with cholic acid; CA+UDCA: diet supplemented with cholic acid + 664 
ursodeoxycholic acid; Hmcr: HMG-coA reductase; Fas: fatty acid synthase. 665 
 666 
Figure 6: Effects of UDCA on liver to body weight ratio and glucose tolerance in offspring 667 
of mouse hypercholanemic pregnancy. A) Effects of UDCA  on liver to body weight ratio 668 
B) Effects of UDCA on glucose tolerance in NC-fed and WD-fed female offspring of maternal 669 
hypercholanemia. Data are presented as mean and standard error of the mean (sem) and were 670 
analyzed with multiple measures of ANOVA followed by Neuman Keul’s post-hoc testing. 671 
$p<0.05 0’ vs 15’, *p<0.05 15’ CA WD vs 15’ NC/CA+UDCA WD, ﹟p<0.05 30’ CA WD 672 
vs 30’ NC/CA+UDCA WD , NC n=6, CA n=6, CA+UDCA n=4. NC/CA/CA+UDCA 673 
represent maternal diet; NC/WD represent offspring diet. LW/BW: liver weight/body weight; 674 
NC: normal chow; WD: western diet; GTT: glucose tolerance test. 675 
 676 
Figure 7: Canonical pathways identified by IPA in the control versus disease comparison 677 
(treated and untreated ICP). Bars represent –log (p value). Continuous line represents p 678 
value threshold equivalent to 0.05. Lines with squares represent the number of molecules in 679 
the dataset that are part of the pathway/number of molecules in the pathway (ratio).  680 
 681 
Figure 8: Disease processes and differentially methylated molecules identified by IPA in 682 
the control versus disease comparison (treated and untreated ICP). A) Biological 683 
processes. Bars represent –log (p value). Continuous line represents p value threshold 684 
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equivalent to 0.05. B) Molecules Hypomethylated in disease C) Molecules hypermethylated in 685 
disease 686 
 687 
Figure 9: Global DNA methylation patterns in placentas from pregnancies affected by 688 
ICP and controls. Data are presented as mean and standard error of the mean (sem). 5-mC%: 689 
percentage of 5-methylcytosie; ICP: Intrahepatic cholestasis of pregnancy. *: p<0.05 690 
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Tables 719 
Comparison  CpG site Status  logFC P.Value Adjusted P value Symbol UCSC Reference Gene Name 
Control versus 
disease  
(treated and 
untreated ICP) 
cg13274534 Hypermethylated in disease -0.243564 4.64E-08 0.02264796 TEX29 testis expressed 29 
cg00720629 Hypermethylated in disease -0.3728101 1.89E-07 0.02264796 TBX1  T- box 1 
cg09781936 Hypermethylated in disease -0.2377453 2.72E-07 0.02264796 TBX1 T-box 1 
cg18351741 Hypermethylated in disease -0.3198715 3.09E-07 0.02264796 DFNB59 deafness, autosomal recessive 59 
cg10034679 Hypermethylated in disease -0.247224 3.19E-07 0.02264796 WDFY4 WDFY family member 4 
cg01520190 Hypermethylated in disease -0.2302545 3.80E-07 0.02264796 AHNAK AHNAK nucleoprotein 
cg17676618 Hypermethylated in disease -0.2464 4.90E-07 0.02544932   
 
 cg16850951 Hypermethylated in disease -0.3245504 8.75E-07 0.03848915   
 
 cg03354554 Hypomethylated in disease 0.47555505 1.79E-07 0.02264796   
 
 
cg23530232 Hypomethylated in disease 0.40697096 2.52E-07 0.02264796 H6PD 
hexose-6-phosphate 
dehydrogenase/ glucose 1-
dehydrogenase 
cg08282819 Hypomethylated in disease 0.40336227 2.59E-07 0.02264796 IL21R interleukin 21 receptor 
cg05018116 Hypomethylated in disease 0.33289686 2.90E-07 0.02264796 BRD4 bromodomain containing 4 
cg10961050 Hypomethylated in disease 0.33797259 3.01E-07 0.02264796 MAMDC2 MAM domain containing 2 
cg25975961 Hypomethylated in disease 0.52015521 3.37E-07 0.02264796   
 
 
cg22559497 Hypomethylated in disease 0.43934031 3.75E-07 0.02264796   
 
 
cg20334115 Hypomethylated in disease 0.50811853 4.00E-07 0.02264796 PYCR2 pyrroline-5-carboxylate reductase 2 
cg25001190 Hypomethylated in disease 0.33147151 5.14E-07 0.02544932 NFIA nuclear factor I A 
cg06313424 Hypomethylated in disease 0.31707252 6.02E-07 0.02803589 WDR70 WD repeat domain 70 
Control versus 
 untreated ICP 
cg03749207 Hypomethylated in untreated 
ICP 1.742272 5.82E-09 0.00460946 PRR25 proline rich 25 
cg02407415 Hypomethylated in untreated 
ICP 1.449036 5.37E-08 0.02125066 PRR25 proline rich 25 
Treated versus  
untreated ICP 
cg03749207 Hypomethylated in untreated 
ICP 1.789117 2.18E-10 0.00017294 PRR25 proline rich 25 
cg02407415 Hypomethylated in untreated 
ICP 1.425257 8.48E-09 0.00335754 PRR25 proline rich 25 
 720 
Table 1: Differentially methylated CpGs and assigned genes in different comparisons. 721 
Statistical analysis was performed using the logit transformed M-values for methylation. 722 
Differentially methylated CpGs were assigned using Limma (version 3.36.1) and adjusted for 723 
status, gender and ethnicity as confounders. A 5% Benjamini-Hochberg False Discovery Rate 724 
(FDR) correction for multiple testing was applied. All dmCpGs were assigned to their 725 
corresponding genomic context and location using the R/Bioconductor package 726 
IlluminaHumaMethylationEPICanno.ilm10b2.hg19 (version 0.6.0). ICP: intrahepatic 727 
cholestasis of pregnancy; logFC: log fold change; UCSC: University of California, Santa Cruz 728 
genome browser.  729 
 730 
 731 
 732 
 733 
 25 
 Pathway n p value 
Kyoto Encyclopedia of 
Genes and Genomes 
(KEGG)  
Pentose phosphate pathway 30 0.018765 
Arginine and proline metabolism 49 0.021207 
Inflammatory bowel disease (IBD) 63 0.03475 
Biosynthesis of amino acids 73 0.037643 
Carbon metabolism 116 0.063953 
Th17 cell differentiation 105 0.081436 
Jak-STAT signaling pathway 152 0.089217 
Cytokine-cytokine receptor interaction 261 0.098618 
Metabolic pathways 1255 0.175827 
Cellular senescence 157 1 
    
Gene ontology (GO) 
interleukin-21 receptor activity 1 0.00058 
pyrroline-5-carboxylate reductase activity 3 0.000959 
glucose 1-dehydrogenase [NAD(P)] activity 1 0.001479 
glucose dehydrogenase activity 1 0.001479 
6-phosphogluconolactonase activity 2 0.001617 
regulation of histone H2B conserved C-terminal 
lysine ubiquitination 1 0.001656 
regulation of DNA double-strand break processing 2 0.001787 
L-proline biosynthetic process 5 0.001903 
proline biosynthetic process 5 0.001903 
positive regulation of skeletal muscle fiber 
differentiation 2 0.002738 
positive regulation of tongue muscle cell 
differentiation 2 0.002738 
regulation of tongue muscle cell differentiation 2 0.002738 
tongue muscle cell differentiation 2 0.002738 
glucose-6-phosphate dehydrogenase activity 2 0.002793 
histone H2B conserved C-terminal lysine 
ubiquitination 2 0.003224 
vagus nerve morphogenesis 2 0.003423 
regulation of histone H2B ubiquitination 5 0.003607 
proline metabolic process 9 0.00394 
regulation of skeletal muscle fiber differentiation 3 0.004158 
skeletal muscle fiber differentiation 5 0.004653 
 734 
Table 2: Canonical pathways identified in the control versus disease comparison (treated 735 
and untreated ICP). Canonical pathways were identified using GO and KEGG tools through 736 
the MissMethyl R package. n= number of genes.  737 
 738 
